Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals — Investor Presentation (January 2021)

26 slides from Dicerna Pharmaceuticals's investor presentation, Jan 12, 2021

  1. Slide 1: Corporate Overview: Discovery to Commercialization RNAi Platform

    Corporate Overview Discovery to Commercialization RNAi Platform January 2021 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materi

  3. Slide 3: Dicerna was founded to specialize in RNAi

    Dicerna was founded to specialize in RNAi Partner of Choice: Several large pharmas have chosen Dicerna for RNAi collaboration The RNAi Modality Has Come of Age RNAi Has Been Successful Where Traditional Modalities Have Not Gene Targeting Across Multiple Tissue Types Approved Products in Multiple Dis

  4. Slide 4: RNAi Delivery Is Extending to Multiple Tissues Beyond the Liver

    RNAi Delivery Is Extending to Multiple Tissues Beyond the Liver The Future Is Bright Alzheimer’s, Parkinson’s, frontotemporal dementia, Huntington’s, spinal cord injury, other rare diseases and more Immuno-oncology Diabetes, obesity, rare diseases and more Diseases of the lung, eye, kidney, etc. Myo

  5. Slide 5: Dicerna Is an Engine of Discovery and Development

    Dicerna Is an Engine of Discovery and Development Core Clinical Pipeline Current pipeline yields multiple major milestones over next year+ Nedosiran: A differentiated potential therapy for all primary hyperoxaluria (PH) types (PH1, PH2 and PH3) RG6346: Potential best-in-class therapeutic with strong

  6. Slide 6: Core and Collaborative Development-Stage Programs

    With 20+ discovery-stage programs in multiple tissues Core and Collaborative Development-Stage Programs Ten Programs Have Entered Development, Many More Are in Discovery Stage TARGET INDICATION COMPOUND (GENE TARGET) PRECLINICAL EARLY CLINICAL TRIALS REGISTRATION TRIALS DICERNA PRODUCT RIGHTS PARTNE

  7. Slide 7: De-Risked RNAi Technology Platform: GalXC

    De-Risked RNAi Technology Platform: & Delivery to Liver, Central Nervous System and Multiple Other Tissue Types Enhanced secondary structures and chemistries RNAi Platform Multiple conjugated delivery elements including GalNAc for liver delivery and proprietary elements and structures for other tiss

  8. Slide 8: Key Value Drivers

    Key Value Drivers Core Clinical Programs Nedosiran for PH Belcesiran for AATLD RG6346 (RO7445482) for chronic HBV Collaborative Programs Roche and Novo opt-in programs Extrahepatic Discovery Efforts Commercial Infrastructure Team and Balance Sheet

  9. Slide 9: Nedosiran for the Treatment of Primary Hyperoxaluria (PH)

    Nedosiran for the Treatment of Primary Hyperoxaluria (PH)

  10. Slide 10: The Disease: Primary Hyperoxaluria

    The Disease: Primary Hyperoxaluria A Family of Ultra-Rare, Life-Threatening Genetic Disorders Resulting in Renal Complications GO = glycolate oxidase LDHA = lactate dehydrogenase A CKD= chronic kidney disease ESRD= end-stage renal disease Kidney function preservation Kidney stones Impacted by ESRD &

  11. Slide 11: The Opportunity: Nedosiran Is the Only RNAi Drug Candidate for All PH Types

    The Opportunity: Nedosiran Is the Only RNAi Drug Candidate for All PH Types Planned Commercial Launch in 1H 2022 comprehensive treatment option for all patients with PH Education Estimated PH Diagnosis Rates PH1 PH2 PH3 Current Diagnosis Projections^ ~40% – 50% ~10% ~7% Diagnostic Testing Patient &

  12. Slide 12: The Data: Average Oxalate Levels Normalized After Nedosiran Treatment

    The Data: Average Oxalate Levels Normalized After Nedosiran Treatment Results From Ongoing Multidose Open-Label PHYOX™3 Trial *One participant was missing Uox value at Day 60; BSA = body surface area adjusted; Uox = urinary oxalate Nedosiran was generally well tolerated, and no serious safety concer

  13. Slide 13: The Plan: Building Dicerna's Commercial Infrastructure

    The Plan: Building Dicerna’s Commercial Infrastructure Striving for Best-in-Class Service to the PH Community Serving a rare disease community requires long-term comprehensive commitment and dedication Education Disease education for HCPs, payors and patients on all aspects of PH Medical Science Lia

  14. Slide 14: RG6346 (RO7445482) for the Treatment of Chronic HBV Infection

    RG6346 (RO7445482) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

  15. Slide 15: The Disease: Chronic HBV is a Severe, Global Unmet Medical Need

    The Disease: Chronic HBV is a Severe, Global Unmet Medical Need Significant worldwide prevalence: ~292 million infected, >880,000 deaths per year Current treatments are rarely effective in achieving functional cures Collaborating with Roche to conduct Phase 2 combination clinical studies with RG6346

  16. Slide 16: The Data: Reductions in HBsAg Levels Ongoing One Year After Last Dose

    Mean HBsAg log10 IU/mL Change From Baseline The Data: Reductions in HBsAg Levels Ongoing One Year After Last Dose NUC-Suppressed Chronic HBV Participants Given 4 Monthly Doses at 1.5, 3 or 6 mg/kg 1.8 log10 mean reduction (IU/ml) of hepatitis B surface antigen (HBsAg) (3 mg/kg and 6 mg/kg cohorts) 2

  17. Slide 17: Belcesiran for the Treatment of AATLD

    Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATLD)

  18. Slide 18: Belcesiran for A1AT Deficiency-Associated Liver Disease

    Belcesiran for A1AT Deficiency-Associated Liver Disease (AATLD) Significant Opportunity In a Rare, Genetic Condition That Can Lead to Liver Disease Z-allele of SERPINA1 gene produces abnormal A1AT protein that may lead to chronic liver disease culminating in cirrhosis, liver failure, cancer. No avai

  19. Slide 19: Corporate Collaborations

    Corporate Collaborations

  20. Slide 20: Successfully Executing on High-Value Collaboration Strategy

    Successfully Executing on High-Value Collaboration Strategy Broad therapeutic areas including rare and common diseases: cardiovascular disease, NASH, cardiometabolic diseases, etc. First collaborative program entered clinic Q4 2020 Expect 2-3 clinical entries in 2021 >20 discovery and preclinical pr

  21. Slide 21: GalXC-Plus Extrahepatic Platform

    Ga XC Plus” Extrahepatic Platform

  22. Slide 22: Broad Opportunity in Tissues Beyond the Liver

    : Broad Opportunity in Tissues Beyond the Liver Future Pipeline and Collaborations to Include Delivery Beyond Liver Dicerna TIDES Europe Presentation, Nov. 10, 2020 100% owned technology Up to 99% gene silencing in non-human primate models from a single dose Rare diseases and large-market neurodegen

  23. Slide 23: Management Team

    Management Team Leading Experts in RNAi Technology, Clinical, Regulatory and Commercial Operations Douglas M. Fambrough, Ph.D. President and Chief Executive Officer Douglas Pagán Chief Financial Officer Rob Ciappenelli Chief Commercial Officer Shreeram Aradhye, M.D. EVP, Chief Medical Officer Bob D.

  24. Slide 24: Strong Balance Sheet

    Strong Balance Sheet Dicerna’s Business Model Has Potential to Fund Robust Pipeline Growth Expect balance sheet to remain strong due to product revenue, payments from existing collaborations, new collaborations, and asset monetization (does not include any proceeds from potential follow-on stock off

  25. Slide 25: Target Milestones To Drive Momentum in 2021

    Target Milestones To Drive Momentum in 2021 Focused on Execution Nedosiran for PH (PH1, PH2, PH3) Complete pivotal enrollment Top-line PHYOX2 pivotal data mid-year 2021 PHYOX4 data in PH3 mid-year 2021 NDA submission Q3 2021 Prepare for 2022 target launch RG6346 for HBV Phase 2 study initiation Q1 2

  26. Slide 26: Dicerna

    ye Dicerna

Dicerna Pharmaceuticals — Investor Presentation (January 2021) on 6ix